C11 ER176 PET in Evaluating Neuroinflammation in Patients... | NCT07527130

Studies
C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

NCT07527130

Sponsor

Mayo Clinic

Status

Not yet recruiting

Last Update Posted

Apr 24, 2026Actual

Enrollment

10Estimated

Phase

Not provided

Conditions

COVID-19

Interventions

C11 ER176 Tracer

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Apr 2026

Overall Recruitment Status or Expanded Access Status

Not yet recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

May 2026Estimated

Primary Completion Date

Dec 2027Estimated

Completion Date

Dec 2027Estimated

First Submitted Date

Apr 7, 2026

First Submission Date that Met QC Criteria

Apr 7, 2026

First Posted Date

Apr 14, 2026Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Apr 21, 2026

Last Update Posted Date

Apr 24, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Yes

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

10Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Post Covid Syndrome		PET imaging through the C11 ER176 tracer	Drug: C11 ER176 Tracer

Interventions

Name	Type	Description	Arm Group Labels	Other Names
C11 ER176 Tracer	Drug	C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation	Post Covid Syndrome

Measure	Description	Time Frame
Degree of Neuroinflammation	Estimation of areas degree of neuroinflammation determined by the radiologist	Baseline reading only

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.
Be able to participate fully in all aspects of the study.
Have understood and signed study informed consent.

Exclusion Criteria:

Lacking the capacity to consent.
Prisoners and institutionalized individuals.
Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.

o Acceptable forms include:
- Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
- Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
- Intrauterine device (IUD)
- Total hysterectomy or tubal ligation
- Abstinence (no sex).
Those patients that have implants that would prevent them from having a PET Scan.
Patients that have claustrophobia.
Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Patients from the Post Covid Care Clinic (PCoCC) through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.

Sampling Method

Non-Probability Sample

ID	Term
D011024	Pneumonia, Viral
D011014	Pneumonia
D012141	Respiratory Tract Infections
D007239	Infections